Gilead Sciences, Inc. (GILD) vs Sanofi (SNY)
Gilead Sciences, Inc. and Sanofi are both Drug Manufacturers General companies. Gilead Sciences, Inc. is the larger, with a market value of $183.2B against $97.4B — 1.9× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Sanofi trades at 21.5×. Sanofi grew revenue faster over the last twelve months: 21.3% against 5.52%. Sanofi has the higher net margin (8.22% vs −10.6%) and the higher return on invested capital (6.58% vs −4.48%). Both pay a dividend; Sanofi yields more (4.40% vs 4.27%). Across the 22 metrics below, Sanofi leads on 17 and Gilead Sciences, Inc. on 5.
Valuation
Profitability
| Metric | GILD | SNY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.59% | 72.78% | 72.77% |
| Operating margin | (8.20%) | 18.24% | 18.90% |
| Net margin | (10.64%) | 8.22% | 8.27% |
| Free cash flow margin | 42.50% | 25.53% | 17.25% |
| Return on equity | (20.68%) | 5.87% | 6.97% |
| Return on assets | (6.17%) | 3.21% | 2.76% |
| Return on invested capital | (4.48%) | 6.58% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack